Spots Global Cancer Trial Database for crizotinib
Every month we try and update this database with for crizotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT00939770 | Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur... | Crizotinib Laboratory Biom... Pharmacological... Questionnaire A... | 1 Year - 21 Years | Children's Oncology Group | |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma | NCT05014464 | Non-small Cell ... | Crizotinib | 18 Years - | Hunan Province Tumor Hospital | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | NCT02727335 | Non-small Cell ... Anaplastic Lymp... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | NCT06140836 | Carcinoma, Non-... | Repotrectinib Crizotinib | 18 Years - | Bristol-Myers Squibb | |
| Treatment With Crizotinib Single Patient Expanded Access IND 134375 | NCT03085186 | Inflammatory My... | Crizotinib | 2 Years - 2 Years | University of Pittsburgh | |
| Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer | NCT03647111 | Non-small Cell ... | Crizotinib | 18 Years - | Hunan Province Tumor Hospital | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | NCT01531361 | Advanced Malign... BRAF Gene Mutat... Metastatic Mali... Recurrent Malig... Refractory Mali... | Crizotinib Laboratory Biom... Pharmacological... Sorafenib Tosyl... Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | NCT05987332 | Metastatic Uvea... | IDE196 Crizotinib Pembrolizumab Ipilimumab Nivolumab Dacarbazine | 18 Years - | IDEAYA Biosciences | |
| Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | NCT04009317 | ALK-positive NS... | TQ-B3139 Crizotinib | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | NCT02207504 | Castration-resi... | Crizotinib Enzalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | NCT02201992 | ALK Gene Rearra... ALK Gene Transl... ALK Positive Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Clinical Observ... Crizotinib Laboratory Biom... | 18 Years - | Eastern Cooperative Oncology Group | |
| Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) | NCT02679170 | Non-Small Cell ... | Crizotinib | 19 Years - | Pfizer | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | NCT04632758 | Non-small Cell ... | WX-0593 Tablets crizotinib | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | NCT02767804 | Non-small Cell ... | X-396 (ensartin... crizotinib | 18 Years - | Xcovery Holdings, Inc. | |
| Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC | NCT04322578 | Non-small Cell ... | Crizotinib | 18 Years - | Hunan Province Tumor Hospital | |
| A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | NCT02435108 | c-MET Positive ... | crizotinib | 20 Years - | Samsung Medical Center | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Study of Crizotinib for ROS1 and MET Activated Lung Cancer | NCT04084717 | Non-squamous No... Stage IV Non-sm... ROS1 Gene Rearr... MET Activating ... MET Amplificati... | Crizotinib | 18 Years - | University Health Network, Toronto | |
| LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | NCT02612194 | Urinary Bladder... Ureteral Neopla... Urethral Neopla... | Crizotinib | 18 Years - | Wake Forest University Health Sciences | |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | NCT01441388 | Carcinoma, Rena... Glioblastoma Carcinoma, Hepa... | Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... | 18 Years - | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | NCT02727335 | Non-small Cell ... Anaplastic Lymp... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients | NCT02511184 | ALK-positive Ad... | Crizotinib Pembrolizumab | 18 Years - | Pfizer | |
| A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | NCT05204628 | Non-small Cell ... | XZP-3621 Crizotinib | 18 Years - 75 Years | Xuanzhu Biopharmaceutical Co., Ltd. | |
| Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | NCT02473497 | Neoplasm | Crizotinib | 0 Years - | Pfizer | |
| Lorlatinib Combinations in Lung Cancer | NCT04292119 | Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC | Lorlatinib Crizotinib Binimetinib TNO155 | 18 Years - | Massachusetts General Hospital | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | NCT01945021 | Non Small Cell ... ROS1 Proto Onco... Crizotinib | Crizotinib | 18 Years - | Pfizer | |
| Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | NCT01644773 | Diffuse Intrins... High-grade Glio... | Crizotinib Dasatinib | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | NCT01121588 | Neoplasms Malig... | Crizotinib | 15 Years - | Pfizer | |
| A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | NCT02487316 | Systemic Anapla... | crizotinib | 18 Years - 65 Years | Peking University | |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | NCT02836847 | Cholangiocarcin... Gallbladder Can... | biological test GEMOX Cetuximab Trastuzumab Gefitinib Lapatinib Everolimus Sorafenib Crizotinib | 18 Years - 80 Years | Shanghai Jiao Tong University School of Medicine | |
| Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) | NCT02679170 | Non-Small Cell ... | Crizotinib | 19 Years - | Pfizer | |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | NCT02183870 | Lung Cancer Adenocarcinoma NSCLC | Crizotinib | 18 Years - | University of Cologne | |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT00939770 | Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur... | Crizotinib Laboratory Biom... Pharmacological... Questionnaire A... | 1 Year - 21 Years | Children's Oncology Group | |
| Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients | NCT01576406 | Advanced Cancer | crizotinib crizotinib crizotinib crizotinib crizotinib | 18 Years - | Pfizer | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer | NCT00965731 | Non-Small Cell ... | Erlotinib Erlotinib PF-02341066 | 18 Years - | Pfizer | |
| A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | NCT05204628 | Non-small Cell ... | XZP-3621 Crizotinib | 18 Years - 75 Years | Xuanzhu Biopharmaceutical Co., Ltd. | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | NCT01979536 | Anaplastic Larg... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Brentuximab Ved... Crizotinib Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Etoposide Ifosfamide Methotrexate | - 21 Years | National Cancer Institute (NCI) | |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | NCT06140836 | Carcinoma, Non-... | Repotrectinib Crizotinib | 18 Years - | Bristol-Myers Squibb | |
| A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | NCT01712217 | Non-small Cell ... | AT13387 Crizotinib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | NCT04693468 | Advanced Malign... Metastatic Mali... Recurrent Malig... | Axitinib Crizotinib Palbociclib Ise... Talazoparib Tos... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT02838420 | Anaplastic Lymp... | Alectinib Crizotinib | 18 Years - | Hoffmann-La Roche | |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | NCT06360575 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Crizotinib Radiologic Exam... | - | National Cancer Institute (NCI) | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | NCT02435108 | c-MET Positive ... | crizotinib | 20 Years - | Samsung Medical Center | |
| A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants | NCT02075840 | Non-Small Cell ... | Alectinib Crizotinib | 18 Years - | Hoffmann-La Roche | |
| Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | NCT02207504 | Castration-resi... | Crizotinib Enzalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Treatment With Crizotinib Single Patient Expanded Access IND 134375 | NCT03085186 | Inflammatory My... | Crizotinib | 2 Years - 2 Years | University of Pittsburgh | |
| S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | NCT02134912 | Adenocarcinoma ... Large Cell Lung... Recurrent Non-s... Stage IV Non-sm... | crizotinib pemetrexed diso... laboratory biom... pharmacological... | 18 Years - | SWOG Cancer Research Network | |
| An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients | NCT02708667 | Non-Small Cell ... | 18 Years - 75 Years | Sun Yat-sen University | ||
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | NCT04009317 | ALK-positive NS... | TQ-B3139 Crizotinib | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer | NCT03646994 | Non-small Cell ... | Crizotinib | 18 Years - | Hunan Province Tumor Hospital | |
| An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients | NCT02708667 | Non-Small Cell ... | 18 Years - 75 Years | Sun Yat-sen University | ||
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) | NCT04439253 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Crizotinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | NCT06357975 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Crizotinib Radiologic Exam... | 18 Years - | National Cancer Institute (NCI) | |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer | NCT04317651 | Non Small Cell ... Advanced Cancer Metastatic Canc... | 18 Years - | Fondazione Ricerca Traslazionale | ||
| eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | NCT02767804 | Non-small Cell ... | X-396 (ensartin... crizotinib | 18 Years - | Xcovery Holdings, Inc. | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | NCT02767804 | Non-small Cell ... | X-396 (ensartin... crizotinib | 18 Years - | Xcovery Holdings, Inc. | |
| Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | NCT03088930 | Lung Cancer, No... | Crizotinib | 18 Years - 100 Years | University of Colorado, Denver | |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | NCT02183870 | Lung Cancer Adenocarcinoma NSCLC | Crizotinib | 18 Years - | University of Cologne | |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | NCT02584634 | Non-Small Cell ... | Avelumab PF-06463922 Crizotinib | 18 Years - | Pfizer | |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | NCT02761057 | Locally Advance... Metastatic Papi... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... Unresectable Re... | Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Crizotinib Savolitinib Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors | NCT03874273 | Inflammatory My... | Crizotinib | - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | NCT02201992 | ALK Gene Rearra... ALK Gene Transl... ALK Positive Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Clinical Observ... Crizotinib Laboratory Biom... | 18 Years - | Eastern Cooperative Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
